study of investigator with Dr. Rivas

Posted By
7/30/2014 11:16am
View other posts by
Activity
Replies: 1

In the 16 and 17 page of thie document there is a interesting study, because oc my english i dont understand as well as i would like, could someone do a easier conclusions?

www.seom.org/seomcms/images/stories/recursos/Boletin_91_pub.pdf

 

 

Thanks

Anonymous - (7/30/2014 - 5:17pm)

I agree, the language in that report is difficult to understand. It might be easier for you to read the original research paper here:

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire (see: http://clincancerres.aacrjournals.org/content/20/9/2424.full )

The bottom line is that anti-CTL-4 antibodies (ipi; Yervoy) seem to increase the diverstiy of the T-cells in 80% of the patients. This may have a bearing on autoimmune side effects. It does not seem to be related to the effectiveness of the treatment.